Prospective real-world analysis of intravenous eptinezumab in migraine patients confirms clinical trial efficacy translates to everyday practice with good tolerability.
Key findingProspective real-world analysis of intravenous eptinezumab in migraine patients confirms clinical tr
What the researchers found
Prospective real-world analysis of intravenous eptinezumab in migraine patients confirms clinical trial efficacy translates to everyday practice with good tolerability.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Patients received eptinezumab 100 mg IV; treatment period up to 6 months. Specific migraine day reductions not detailed in abstract.
How the study worked
In publication.
Who was studied
Adults with migraine treated with IV eptinezumab in the UK per NICE guidelines
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
A prospective real-world analysis of intravenous eptinezumab in migraine management: the first UK experience.
The journal of headache and pain, 26(1), 235
Citation
Andreou, Anna P; Hill, Bethany; Al-Rawi, Rand; Murphy, Madeleine; Soares, Isabel; Briscoe, Jessica; Kilner, Rachael; Lambru, Giorgio. (2025). A prospective real-world analysis of intravenous eptinezumab in migraine management: the first UK experience.. The journal of headache and pain, 26(1), 235. https://doi.org/10.1186/s10194-025-02180-3